易瑞生物
(300942)
| 流通市值：45.00亿 | | | 总市值：45.00亿 |
| 流通股本：4.05亿 | | | 总股本：4.05亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 449,803,934.39 | 397,216,726.53 | 419,229,213.25 | 293,399,311.14 |
| 交易性金融资产 | 145,046,268.56 | 139,506,128.75 | 162,273,362.12 | 302,915,183.87 |
| 衍生金融资产 | 771,150.84 | 1,198,329.56 | 237,652.07 | - |
| 应收票据及应收账款 | 100,412,073.93 | 90,149,457.06 | 81,780,518.1 | 94,108,738.25 |
| 其中：应收票据 | 681,861.96 | 220,936 | 31,055 | 50,000 |
| 应收账款 | 99,730,211.97 | 89,928,521.06 | 81,749,463.1 | 94,058,738.25 |
| 预付款项 | 4,769,315.8 | 5,466,489.87 | 8,425,836.26 | 4,905,642.34 |
| 其他应收款合计 | 4,129,538.63 | 5,195,502.84 | 4,729,840.96 | 5,799,009.22 |
| 存货 | 57,910,460.72 | 52,711,532.65 | 40,907,172.43 | 40,430,062.74 |
| 其他流动资产 | 12,530,986.09 | 10,784,236.56 | 13,348,878.35 | 10,058,204.33 |
| 流动资产合计 | 775,373,728.96 | 702,228,403.82 | 730,932,473.54 | 751,616,151.89 |
| 非流动资产: | | | | |
| 长期股权投资 | 84,480,660.5 | 96,970,169.15 | 99,961,461 | 100,689,968.41 |
| 固定资产 | 570,435,095.39 | 501,684,913.54 | 358,753,842.93 | 363,111,336.95 |
| 在建工程 | 6,805,858.89 | 70,901,095.38 | 211,091,768.42 | 199,792,641.95 |
| 无形资产 | 37,787,164.35 | 38,272,447.23 | 38,757,730.11 | 39,243,012.99 |
| 长期待摊费用 | 2,803,768.73 | 1,722,757.31 | 1,740,940.48 | 1,676,331.65 |
| 递延所得税资产 | 2,901,758.03 | 1,324,627.17 | 879,976.78 | 79,078.8 |
| 其他非流动资产 | 972,000 | 7,049,966.93 | 957,413.28 | 957,413.28 |
| 非流动资产合计 | 706,186,305.89 | 717,925,976.71 | 712,143,133 | 705,549,784.03 |
| 资产总计 | 1,481,560,034.85 | 1,420,154,380.53 | 1,443,075,606.54 | 1,457,165,935.92 |
| 流动负债: | | | | |
| 衍生金融负债 | - | 0 | 0 | 34,645.41 |
| 应付票据及应付账款 | 74,837,634.92 | 57,880,217.3 | 51,219,299.39 | 58,762,442.61 |
| 应付账款 | 74,837,634.92 | 57,880,217.3 | 51,219,299.39 | 58,762,442.61 |
| 预收款项 | 431,047.48 | 693,052.66 | 955,551.92 | 109,647.69 |
| 合同负债 | 16,860,113.84 | 17,312,180.03 | 19,356,363.94 | 24,992,820.15 |
| 应付职工薪酬 | 17,618,216.62 | 16,514,048.27 | 12,695,672.67 | 18,699,553.31 |
| 应交税费 | 1,437,542.2 | 717,107.11 | 2,576,004.67 | 790,691.67 |
| 其他应付款合计 | 5,099,993 | 3,496,126.68 | 3,796,243.69 | 4,423,186.14 |
| 一年内到期的非流动负债 | 31,991,821.43 | 11,026,204.1 | 40,618,945.61 | 41,598,111.04 |
| 其他流动负债 | 2,027,909.98 | 1,836,564.83 | 2,479,485.46 | 2,546,642.23 |
| 流动负债合计 | 150,304,279.47 | 109,475,500.98 | 133,697,567.35 | 151,957,740.25 |
| 非流动负债: | | | | |
| 长期借款 | 160,533,880.61 | 163,941,237.36 | 166,482,190.93 | 163,217,749.82 |
| 应付债券 | 251,959,949.58 | 273,805,895.29 | 268,456,594.89 | 263,168,579.26 |
| 预计负债 | 2,080,000 | 2,080,000 | 2,080,000 | 2,080,000 |
| 递延收益 | 6,330,243.9 | 5,431,446.3 | 6,010,896.22 | 6,499,295.61 |
| 非流动负债合计 | 420,904,074.09 | 445,258,578.95 | 443,029,682.04 | 434,965,624.69 |
| 负债合计 | 571,208,353.56 | 554,734,079.93 | 576,727,249.39 | 586,923,364.94 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 405,068,607 | 401,317,665 | 401,317,397 | 401,316,667 |
| 其他权益工具 | 62,380,255.73 | 68,386,086.89 | 68,386,319.97 | 68,387,934.52 |
| 资本公积 | 220,636,393.34 | 190,223,361.02 | 190,220,990.47 | 190,215,233.93 |
| 其他综合收益 | -164,030.37 | -19,980.33 | 38,858.13 | -55,803.95 |
| 盈余公积 | 55,512,481.54 | 55,512,481.54 | 55,512,481.54 | 55,512,481.54 |
| 未分配利润 | 164,656,669.77 | 148,973,123.19 | 150,282,821.49 | 153,628,825.18 |
| 归属于母公司股东权益合计 | 908,090,377.01 | 864,392,737.31 | 865,758,868.6 | 869,005,338.22 |
| 少数股东权益 | 2,261,304.28 | 1,027,563.29 | 589,488.55 | 1,237,232.76 |
| 股东权益合计 | 910,351,681.29 | 865,420,300.6 | 866,348,357.15 | 870,242,570.98 |
| 负债和股东权益合计 | 1,481,560,034.85 | 1,420,154,380.53 | 1,443,075,606.54 | 1,457,165,935.92 |
| 公告日期 | 2025-10-28 | 2025-08-28 | 2025-04-25 | 2025-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |